Source: POLITICO'S MORNING AGRICULTURE 1/31/19

As U.S. and Chinese trade officials negotiate in Washington, biotech advocates are concerned their priorities might be left out of a potential deal.

The Biotechnology Innovation Organization said China needs to agree to take more action on approving genetically modified crops, and the group wants Trump to insist on such provisions, Pro Trade's Doug Palmer reports.

"Any prospective trade deal with China cannot be based simply on a promise to buy more U.S. products," said BIO President Jim Greenwood. "Such a bargain would fail to address the long-standing impediments that have contributed to the trade deficit with China."

Opportunity cost: The trade group said China's delays in approving biotech crops have resulted in foregone U.S. economic growth of nearly 34,000 jobs.